Toggle Health Problems and D

Multiple sclerosis helped some by 10,000 IU of vitamin D daily avg. for 3 months – RCT Sept 2016

High dose Vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial.

Neurol Res. 2016 Sep 6:1-5. [Epub ahead of print]
Ashtari F1, Toghianifar N2, Zarkesh-Esfahani SH3, Mansourian M4.
1a Department of Neurology , Isfahan University of Medical sciences , Isfahan , Iran.
2b Isfahan Neuroscience Research Center , Isfahan University of Medical Sciences , Isfahan , Iran.
3c Department of Biology , University Of Isfahan , Isfahan , Iran.
4d Department of Biostatistics and Epidemiology, Health School , Isfahan University of Medical Sciences , Isfahan , Iran.


This study used 50,000 IU every 5 days for only 3 months - far too small of dose for too short of a time
MS has been cured with 2.4 to 30 times higher dose sizes - which vary with the person

Low level of vitamin D is associated with a more severe course and low quality of life in relapsing-remitting multiple sclerosis (RRMS). Low dose vitamin D intake has improved quality of life in RRMS patients.

This study explored the effect of high dose vitamin D intake on quality of life in RRMS patients in a double blind randomized clinical trial.

94 RRMS patients were randomized to two groups. One group received 50,000 IU vitamin D3 every five days for 3 months. The other group received placebo. Interferon-ß (IFN-ß) continued as the main treatment in both groups. Quality of life was assessed using MSQOL-54 Persian version at the beginning and at the end of the study.

After 3 months, the vitamin D group had a significant difference in mental health composite with placebo group, 62.41 ± 13.99 vs. 60.99 ± 17.99 (p-value = 0.041). Change in health was 75.74 ± 25.73 and 70.59 ± 26.45 in vitamin D and placebo group, respectively (p-value = 0.036).

Mental QOL improved significantly after taking high dose vitamin D for 3 months in vitamin D group relative to placebo.

PMID: 27597724 DOI: 10.1080/01616412.2016.1227913

Publisher wants $54 for the PDF